ARS Pharmaceuticals, Inc (SPRY) — Cash Flow Reinvestment Rate
ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Reinvestment Rate of 2.43x as of December 2024, reinvesting $102.06 Million (capex $302.00K plus investments $-101.76 Million) from operating cash flow of $42.00 Million. See how much free cash does ARS Pharmaceuticals, Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ARS Pharmaceuticals, Inc Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for ARS Pharmaceuticals, Inc across 2 annual periods. For the full cash flow conversion analysis, see SPRY operating cash flow.
Annual Cash Flow Reinvestment Rate for ARS Pharmaceuticals, Inc (2020–2024)
Year-by-year capital reinvestment analysis for ARS Pharmaceuticals, Inc. See ARS Pharmaceuticals, Inc (SPRY) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.87x | $106.66 Million | $13.55 Million | $563.00K | ▲ +7688.0% |
| 2020 | 0.10x | $917.00K | $9.07 Million | $917.00K | — |